Anti-senescence therapies, such as drugs that specifically kill senescent cells, to stave off ageing are currently under investigation. While these interventions show promise, their potential pitfalls are discussed herein. We have shown that the mitochondria are essential for development of senescence and many of the associated phenotypes, including the often detrimental senescence-associated secretory phenotype (SASP). Here, we disentangle many ways in which the mitochondria may influence senescence and development of the SASP and focus on possible pathways that could be exploited for future generation of antisenescence therapies with a clear aim; to specifically eliminate the problematic features of senescent cells, while maintaining their beneficial characteristics.
Introduction
Cellular senescence, the irreversible loss of replicative potential in somatic cells, was described over 50 years ago when it was observed that normal human fibroblasts undergo a finite number of divisions before ceasing to proliferate in culture [1] . This was subsequently termed "replicative senescence" but we now know that multiple stressors can cause senescence, way before replicative exhaustion has taken hold, including oxidative stress, chromatin modifications, and oncogene activation [2] . Evidence suggests that senescence is a potent anticancer mechanism in vivo, preventing cellular transformation [3] . However, somehow paradoxically, senescent cells are causally implicated in the ageing process and in carcinogenesis in vivo. With this double-edged sword at play, it is a major challenge to selectively target senescent cells in order to inhibit their deleterious effects, while preserving their beneficial characteristics. This notion is further compounded by recent reports implicating senescence in other essential biological processes, such as development and wound healing [4, 5] . We have recently demonstrated that clearance of mitochondria inhibits the development of many senescence-associated features, while maintaining cell-cycle arrest [6] . While a current focus in the ageing field is to uncover therapies that are able to induce senescent cell death, specifically, using drugs termed "senolytics", we propose that targeting key mitochondrial pathways may hold more promise; effectively manipulating the senescent phenotype to preserve only the beneficial aspects, such as the tumor suppressive cell-cycle arrest. Here, we highlight ways by which the mitochondria could be harnessed to alleviate senescence and discuss the factors to consider when targeting senescent cells in vivo.
Senescence and ageing
The activation of a DNA damage response (DDR) is almost always a prerequisite for cellular senescence, converging on two main pathways: the p53-p21 and p16INK4A-pRb tumor suppressor pathways, which establish and maintain cellcycle arrest [3] . Over the past decade, evidence implicating senescence in the ageing process has mounted, with studies reporting age-related increases in senescent cells in tissues from rodents and primates [7] [8] [9] [10] [11] . Studies have also indicated that senescence inducers, such as telomere dysfunction and activation of pathways downstream of the DDR, can accelerate the ageing process [12] . However, it is difficult to determine causality, since other cellular responses, like apoptosis, can be triggered by these stresses. Only recently has a causal link between senescence and the ageing process been effectively demonstrated. Using a transgenic mouse model (INK-ATTAC), Baker et al. found that elimination of p16ink4a-positive senescent cells decreased the DOI 10.1002/bies.201600235 onset of age-related pathologies in both progeroid [13] and wild-type mice [14] . Similarly, using another mouse model, elimination of naturally occurring p19Arf-positive cells (another cell-cycle inhibitor implicated in senescence) restored lung compliance, structure, and elasticity in aged mice [15] . Senescence has been associated with chronic inflammatory diseases that are largely agerelated, including osteoarthritis (OA) [16] and many respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and bronchiectasis [7, 17] . More recently, senescence was causally implicated in disease development, when transplantation of senescent cells into the knee joints of mice induced an OAlike-phenotype [18] . How senescent cells contribute to ageing and disease development in vivo is of great interest, with the most plausible explanation residing in the pro-inflammatory mediators they release, including cytokines, chemokines, and proteases; the so-called senescence-associated secretory phenotype (SASP) [19] . The SASP has both autocrine and paracrine effects, reinforcing senescence and inducing senescence in nearby cells [20, 21] . Furthermore, evidence suggests that the SASP can signal the immune system for senescent cell clearance, which may become defective with age, leading to amplified inflammatory responses and development of chronic inflammatory disease [22, 23] . The SASP may also promote tumorigenesis, by causing microenvironments that favor survival and progression of neoplastic cells and by inducing malignant phenotypes through paracrine mechanisms [19, 24] . While there is no direct evidence causally implicating the SASP specifically in the ageing process, a number of studies have shown that inhibition of the key transcriptional regulator of the SASP (NF-kB), improves lifespan and health span during ageing [25] [26] [27] [28] . Therefore, these studies suggest that the SASP could be a potential target for anti-ageing therapies.
Mitochondria are necessary for senescence
It has been thought for some time that mitochondria are important for senescence with studies showing that mitochondrial-derived reactive oxygen species (ROS) are involved in induction and maintenance of senescence through feedback loops replenishing the DDR [29, 30] . Furthermore, mitochondrial dysfunction has been shown to generate single-strand breaks in telomere regions, which contributes to telomere shortening, culminating in senescence [30, 31] . Recently, mitochondrial dysfunction was shown to induce a distinct type of senescence termed MiDAS (mitochondrial dysfunction-associated senescence), and in mice with a deficiency in the mitochondrial DNA (mtDNA) polymerase PolG that causes increased mtDNA mutations with age, senescent cells accumulate [32] . Experimentally, it is difficult to dissect the mitochondriaassociated processes that could contribute to senescence. Firstly, mitochondria are sophisticated organelles, housing a myriad of chemical reactions necessary for metabolism and energy production. Secondly, it is well established that any perturbation of mitochondrial function may result in adaptive mechanisms that feedback into senescence-inducing pathways, subsequently affecting establishment of causality. Thirdly, analysis of mitochondrial function often relies on isolation of mitochondria and assessments in artificial environments. Finally, measuring ROS in live-cells and in tissues is technically very challenging. Therefore, we recently designed a proof-of-principle experiment, which interrogated whether mitochondria are truly necessary for senescence [6] . Utilizing Parkin-mediated mitophagy to completely remove mitochondria upon their depolarization, we found that following a variety of senescence triggers (e.g. oxidative stress and oncogene activation) features of cellular senescence, including the SASP, were suppressed [6] . Paradoxically, despite decreases in p21 and p16, mitochondrial clearance did not rescue cell-cycle arrest, suggesting that mitochondria are key to the regulation of proinflammatory features of senescent cells and may be promising targets for anti-SASP therapies.
Regulating the SASP: A role for mitochondria?
Recently, several mitochondrial processes have been implicated in the regulation of pro-inflammatory phenotypes. However, these processes are poorly investigated in cellular senescence and while there are many potential pathways driving the SASP (Fig. 1) , there is much still to be elucidated. The positive feedback loop linking mitochondrialderived ROS to persistent DDR signaling "locks" cells in a senescent state and leads to development of senescence-associated phenotypes, including the SASP [29] . Moreover, persistence of a DDR has been shown to contribute to the SASP since inhibition of the ATM kinase, a key initiator of the DDR, suppresses the SASP [33] . Mechanistically, ATM activates NEMO which then activates the IKK complex resulting in nuclear translocation of NF-kB, the major factor regulating transcription of many SASP-associated components [34] .
mTOR and mitochondrial crosstalk in SASP regulation
The mechanistic target of rapamycin (mTOR) is a serine threonine kinase believed to be particularly important to the ageing process, since inhibition with rapamycin extends lifespan and healthspan in a range of model organisms [35, 36] . mTOR signaling has been implicated in both regulation of mitochondrial homeostasis and the SASP. We have recently identified a novel pathway linking the DDR with increased mitochondrial biogenesis through transcriptional activation of PGC1-b, a mitochondrial biogenesis regulator [6] . We found that activation of ATM resulted in activation of AKT and mTOR complex 1 (mTORC1), leading to PGC1-bdependent mitochondrial biogenesis and ROS production, maintaining persistent activation of the DDR and stabilizing the SASP. mTOR inhibition resulted in decreased mitochondrial content in both senescent human and mouse cells. Furthermore, it reduced ROS and activation of a DDR, consistent with the concept that ROS maintains the DDR during senescence [6] . Interestingly, mTOR inhibition and lentiviral mediated knock-down of PGC1-b, despite reducing other features of senescence in human fibroblasts, did not rescue the cell-cycle [6] . Additionally, mTOR can directly regulate the expression of SASP factors at the mRNA and protein levels, independently of the mitochondria and DDR. For instance, mTOR has been shown to regulate the translation of MAPKAPK2 kinase, which phosphorylates and inhibits the RNA binding protein ZFP36L1 during senescence, limiting its ability to degrade mRNA transcripts of numerous SASP factors [37] . mTOR also promotes translation of certain early SASP factors, including IL-1a, which is a membrane bound cytokine that can promote activity of NF-kB [26] .
Mitochondrial metabolism in SASP regulation
Senescent cells are metabolically active but the role of metabolism in cellular senescence is only recently being uncovered, with studies suggesting that the SASP is closely linked to the metabolic state of the cell [38] . Glycolysis, which generates NADH and pyruvate from glucose, ATP and NADþ in the cytosol, is enhanced as cells undergo replicative senescence [39] and many transcripts of enzymes involved in glycolysis are upregulated during senescence [40] . Mechanistically, enhanced glycolysis may contribute to development of senescent phenotypes by impacting on p53, since p53 acts to limit the glycolytic activity Figure 1 . Possible mechanisms whereby mitochondria can impact on the senescenceassociated secretory phenotype. There are many ways in which mitochondria could influence the development of the senescence-associated secretory phenotype (SASP). A positive feedback loop between the DNA damage response (DDR) and the mechanistic target of rapamycin (mTOR)-mediated mitochondrial biogenesis has been described, whereby mitochondrial-derived reactive oxygen species (ROS) replenish DNA damage foci and DDR signaling following initial senescence-inducing stimuli. This is mediated by the mitochondrial biogenesis factor PGC1-b and involves the DNA damage response kinase ATM and AKT. Persistent DDR signaling leads to senescence induction and development of the SASP. ATM can also impact directly on the SASP via phosphorylation and activation of NEMO, which then activates the IKK complex resulting in nuclear translocation of NF-kB, the major factor regulating transcription of many SASP-associated components. mTOR can also directly affect the SASP by controlling factors that stabilise mRNA transcripts and through influencing translation of early SASP factors that modulate NF-kB activity. Shifts in metabolite status, such as low NADþ/NADH and increases in AMP:ATP and ADP:ATP ratios, impact on the SASP indirectly through other modulators of NF-kB activity. Sirtuins require NADþ as a cofactor and are inhibitors of NF-kB activity and maintain transcriptionally silent chromatin, regulating gene expression of many SASP factors. Similarly, poly-ADP ribose polymerases (PARPs), such as PARP1, require NADþ as a donor of ADP-ribose, required for DNA repair following genotoxic stress. Thus low NADþ leads to senescence induction and SASP development. AMP-activated protein kinase (AMPK) is activated by high AMP and ADP levels and can influence the SASP by activation of p53 and by stabilising p21 and p16 mRNA, ultimately resulting in senescence and development of the SASP. of senescent cells [41] . Additionally, pyruvate, which enters the mitochondrial matrix and feeds into the tricarboxylic acid (TCA) cycle as acetylcoenzyme A (acetyl-CoA) following decarboxylation by pyruvate dehydrogenase (PDH), may be important to senescence induction, since supraphysiological levels reduce replicative lifespan of fibroblasts in vitro [42] . Additionally, in oncogene induced senescence (OIS), PDH kinase 1 (an inhibitor of PDH), is suppressed leading to enhanced usage of pyruvate in the TCA cycle [43] . Low NADþ/NADH ratios also promote senescence [38] . NADþ is required for poly-ADP ribose polymerases (PARPs), the main repairers of genotoxic stress-induced damage, and inhibition of PARP-1 maintains DNA damage and sensitizes cells to senescence in vitro [44] . Moreover, NADþ is a co-factor for sirtuins, a family of histone and protein deacetylases. Sirtuins impact on senescence in various ways, including regulating NF-kB activity and in maintaining transcriptionally silent chromatin of NF-kB-dependent genes, such as SASP factor transcripts [45] . Increases in AMP:ATP and ADP:ATP ratios have been linked to the senescence state. AMP-activated protein kinase (AMPK) is a regulator of cellular responses to energy stress and is activated by increased AMP and ADP, which then regulates a series of responses including mitochondrial biogenesis and glucose uptake [46] . AMPK can also lead to phosphorylation and activation of p53, promoting cell-cycle arrest via transcriptional upregulation of p21 [47] and can inhibit Hu antigen R-dependent degradation of p21 and p16 mRNA [48] . Additionally, a low NADþ/NADH ratio leading to AMPK activation was proposed as a mechanism mediating MiDAS, with a distinct SASP, in the aforementioned study [32] . Interestingly, macrophages activated by pro-inflammatory stimuli undergo metabolic reprogramming, whereby mitochondria shift to a more glycolytic state and produce ROS, promoting a pro-inflammatory response [49] , directly linking mitochondrial metabolism to pro-inflammatory cellular responses. The above studies suggest that understanding metabolic control of senescence and the SASP may be crucial for development of therapies for age-related disease.
Mitochondrial DAMPs and the SASP
An additional, more recently explored mechanism by which mitochondria may impact on the SASP involves mitochondrial DNA (mtDNA). mtDNA predominantly encodes components of oxidative phosphorylation and contains unmethylated CpG islands, similar to bacterial DNA [50] . Bacterial DNA and other pathogenic stimuli, such as viral RNA, can activate innate immune receptors, known as pattern recognition receptors (PRRs). Similarly, components released from cells during damage, termed damage associated molecular patterns (DAMPS) can also activate PRRs. mtDNA is one such immunostimulatory factor when present outside of the mitochondrial matrix [50] . Indeed, several signaling pathways sense mtDNA in the cytoplasm, including the NLRP3 inflammasome, which converges on NF-kB [51] and the cytosolic sensor of DNA: the cGAS-STING pathway, which ultimately leads to the expression of type I interferon genes and an anti-viral innate immune responses [52] . Interestingly, exposure to cigarette smoke, an inducer of senescence and the key risk factor for COPD, causes mtDNA release [53] . mtDNA may, therefore, be important to development of proinflammatory phenotypes, but its role in senescence is unknown. The SASP can be induced by activation of cytosolic sensors, potentially independently of mitochondria; innate immune sensors IFI16 and AIM2 have been shown to play a role in modulating senescence [54] . The source of cytosolic DNA during senescence is unclear but it is possible that DNA may leak from the nucleus À something described during deep senescence [55] .
Eliminating senescent cells: Mitochondria, friend or foe?
Although several pieces of evidence suggested a role for senescence during ageing in vivo, only recently has senescence been uncovered as an active contributor to the process [13, 14] . These proof-of-principle experiments led to the idea that one could develop drugs to selectively kill senescent cells. The current senolytics under investigation work by targeting prosurvival and anti-apoptotic pathways specifically activated in senescent cells. Dasatinib is a tyrosine kinase inhibitor known to interfere with suppression of apoptosis and quercetin is a flavonol and inhibitor of phosphatidylinositol-4,5-bisphosphate 3-kinases (PI3Ks) that regulate multiple cellular functions, including survival. When given in combination (D þ Q), they reduce senescent cell burden in aged, radiationexposed and progeroid mice and improve health span, including cardiac function [56] . D þ Q administration also reduced senescent cell frequencies and improved established age-associated vascular phenotypes, such as aortic calcification, in aged and hypercholesterolaemic mice [57] . Researchers have shown that D þ Q reduces expression of BCL-xL (an anti-apoptotic protein from the BCL-2 family) in both senescent preadipocytes and HUVEC cells [56] . Inhibitors of the BCL-2 family are also senolytic in vitro, such as navitoclax (ABT-263) [58] . Navitoclax effectively depletes senescent cells, including senescent bone marrow hematopoietic stem cells and senescent muscle stem cells, in sub-lethally irradiated and physiologically aged mice [59] . BCL-2 family members act upstream of mitochondrial-dependent apoptosis, protecting mitochondrial outer membrane integrity by binding to the pro-apoptotic Bax and Bak, which permeabilize the mitochondrial outer membrane, leading to release of cytochrome C, caspase activation, and rapid cell death [60] .
Nevertheless, there are potential downsides to utilizing therapies targeting anti-apoptotic mechanisms. Recently, it was described that BH3 mimetics could activate a process known as incomplete mitochondrial outer membrane permeabilization (MOMP) [61] . This type of MOMP has been designated "minority MOMP" (miMOMP) since only a minor portion of the mitochondria within the cell undergo MOMP following a sub-lethal stress. miMOMP causes limited caspase activation, which is insuffi-cient to trigger cell death but leads to caspase-dependent DNA damage and genomic instability, promoting tumorigenesis [61] . miMOMP could well be a relevant "side effect" of senolytic drugs, such as the BCL-2 inhibitors, that should be explored. While these senolytics selectively kill senescent cells, the long-term effects on young tissues have not yet been adequately investigated. It could be that miMOMP induction in healthy neighboring cells causes genomic instability, leading to tumorigenesis or possibly accelerated ageing due to caspasedependent DNA damage (Fig. 2) . A better approach may be to target mitochondrial homeostasis and metabolism to specifically suppress the SASP. To generate therapeutics with specific effects on the SASP, the metabolomic networks involved, such as glycolysis, AMPK activation and NADþ sensing need to be further elucidated in senescence. Experiments are needed to determine what components of these pathways are of particular importance and how inhibiting or augmenting certain aspects would fare in young, healthy cells, in addition to how they may suppress senescence-associated inflammation.
Conclusions and prospects
The SASP may be a key target for antiageing therapies. However, given the complexity of functions occurring within mitochondria, we are still ignorant as to what factors can be targeted in order to counteract the SASP. Our experiments revealed a key role for mitochondria in SASP regulation but more work is needed to identify specific targets for interventions that are able to suppress the SASP, while maintaining cell-cycle arrest. Anti-oxidants have been shown to suppress the DDR, but may not be the most adequate, since they may allow cell-cycle progression [62] . Other interventions such as mTOR inhibition offer better promise, particularly since they reduce ROS and the DDR, but do not allow cell-cycle progression. However, mTOR inhibitors, particularly rapamycin, may not be adequate for use in the clinic since they have many negative side-effects. Moreover, if senolytics or SASP suppressors are to be used in the clinic, Figure 2 . miMOMP: potential side effects of senolytics. Senescent cells overexpress antiapoptotic proteins such as BCL-2 family members, which protect mitochondrial outer membrane integrity by binding to the pro-apoptotic BCL-2 members: Bax and Bak. Many of the current senolytic drugs under investigation work by inhibiting these anti-apoptotic proteins, leading to mitochondrial outer membrane permeabilization (MOMP), cytochrome C release, widespread activation of caspases and ultimately apoptosis. In young cells that do not overexpress anti-apoptotic factors, inhibitors of these proteins are known to induce minority MOMP (miMOMP), whereby a small portion of the mitochondria in the cell undergo MOMP, leading to cytochrome C release and limited caspase activation. While this level of caspase activity is not sufficient to induce apoptosis, increased DNA damage can occur, which could potentially lead to genomic instability and cancer. It is also possible that caspase-induced DNA damage can cause premature senescence and accelerated ageing in neighboring non-senescent cells. the timing of interventions needs to be carefully calculated given that senescence may have beneficial functions early on. The reliance on inhibition of anti-apoptotic proteins to kill senescent cells may result in sub-lethal caspase activity that may induce unwanted DNA damage, the consequences of which should be fully investigated. A better approach may be to target specifically pathways regulating the SASP. Nevertheless, targeting the SASP and its regulatory pathways as a therapeutic approach needs careful consideration, particularly since the SASP has been involved in beneficial effects such as immune clearance of senescent cells and wound healing. Future anti-ageing strategies need to impact on the negative aspects of the SASP, while maintaining its positive roles. However, in order to do this, we require further understanding of the SASP regulatory mechanisms and its role in different cell types and tissues during organismal ageing.
